Healthcare- pharmaceutical- and biotech companies are gearing up to tap new markets as they look to consolidate their positions after a spate of mergers & acquisitions and licensing partnerships in 2018. The highest valued deal proved to be of Takeda's acquisition of Shire for $57B with the focus on global R&D- its robust and modality-diverse…